STOCK TITAN

Rapid Micro Biosystems (RPID) Stock News, Feb-Sep 2022

RPID NASDAQ

Rapid Micro Biosystems, Inc. reports news about its life sciences automation business for microbial quality-control testing in healthcare manufacturing. The company develops and sells the Growth Direct platform, proprietary consumables, LIMS connectivity, software and services used to automate microbial analysis for pharmaceuticals, medical devices and personal care products.

Recurring updates include financial results and guidance, Growth Direct system placements and validations, customer orders from global biopharma and CDMO manufacturers, and company participation in healthcare investor conferences. News also covers equity compensation actions and Nasdaq-related employment inducement grants tied to its public-company governance.

Rhea-AI Summary

Rapid Micro Biosystems (Nasdaq: RPID) announced that CEO Robert Spignesi will present at the 2022 PDA/FDA Joint Regulatory Conference on September 14. His session, titled “The Microbiology Lab of the 21st Century”, will address challenges faced by global pharmaceutical companies and the role of automation and digitization in modernizing microbial quality control in manufacturing. The session starts at 7:15 AM ET and will last approximately 25 minutes, followed by a Q&A with Kham Nguyen.

Investors can register for a live webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.10%
Tags
conferences fda approval
-
Rhea-AI Summary

Rapid Micro Biosystems reported Q2 2022 commercial revenue of $3.9 million, down from $5.7 million in Q2 2021. Recurring revenue grew 31% to $2.5 million, now representing 65% of total revenue. The company has lowered its full-year revenue guidance to at least $17.0 million, citing slower system placements and macroeconomic uncertainties. An organizational restructuring plan has been announced, aiming for $8.0 - $9.0 million in annual cost savings. The company rejected a takeover proposal from Kennedy Lewis Investment Management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.13%
Tags
-
Rhea-AI Summary

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) has announced its Board of Directors' unanimous rejection of a non-binding proposal from Kennedy Lewis Investment Management to acquire the company for $5.00 per share. The Board has engaged Morgan Stanley as financial advisor to explore strategic alternatives, including potential sale or merger. Additionally, a limited-duration stockholder rights plan was adopted to protect shareholder value, with rights triggered if ownership exceeds 15%. The plan will expire after the 2023 Annual Meeting unless approved by shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.13%
Tags
none
Rhea-AI Summary

Rapid Micro Biosystems (Nasdaq: RPID) is set to release its second quarter 2022 financial results on August 12, prior to market open. A management webcast will follow at 8:30 a.m. EST, accessible on the Company’s website. The Company specializes in automation solutions for healthcare product manufacturing, enhancing microbial quality control testing through its flagship Growth Direct System. This innovation improves efficiency, accuracy, and compliance, supporting the safe production of biologics, vaccines, and therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
-
Rhea-AI Summary

Rapid Micro Biosystems has received an unsolicited proposal from Kennedy Lewis Investment Management to acquire all outstanding shares for $5.00 per share in cash. The Board of Directors will review this non-binding offer in line with its fiduciary duties, emphasizing that shareholders do not need to take any action at this time. The company specializes in automation solutions aimed at enhancing the manufacturing and release processes for healthcare products, including biologics and vaccines, and is headquartered in Lowell, Massachusetts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.22%
Tags
none
-
Rhea-AI Summary

Kennedy Lewis Investment Management LLC is proposing to acquire Rapid Micro Biosystems (RPID) for $5.00 per share in cash, reflecting a 57% premium over its last closing price of $3.18 on June 29, 2022. As of now, Kennedy Lewis holds approximately 14.14% of RPID's Class A common stock. The firm believes that taking RPID private could enhance its operational value and support stakeholders. The proposal is contingent upon due diligence and final agreement terms, which Kennedy Lewis is prepared to pursue swiftly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.22%
Tags
Rhea-AI Summary

Rapid Micro Biosystems reported first quarter 2022 commercial revenue of $4.2 million, down from $4.8 million in Q1 2021.

Recurring commercial revenue grew by 66% to $2.7 million. The company reaffirmed its full-year 2022 revenue outlook of $27 million to $32 million, expecting growth of 25% to 50% year-over-year. The net loss decreased to ($14.9 million) from ($22.1 million) in Q1 2021. Cash and investments totaled $184.2 million, with no debt. System placements are anticipated to peak in Q4 2022 as access to customer sites improves.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
-
Rhea-AI Summary

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) will announce its first quarter 2022 financial results on May 10, 2022, before the market opens. A webcast conference call hosted by management will follow at 8:30 a.m. EDT, accessible via the company’s investor relations website. The company specializes in life sciences technology, focusing on automation solutions that enhance the manufacturing and quality control processes for healthcare products, including biologics and vaccines. Their Growth Direct System modernizes microbial quality control testing across pharmaceutical manufacturing globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
-
Rhea-AI Summary

Rapid Micro Biosystems (Nasdaq: RPID) reported a fourth quarter total revenue of $5.2 million for 2021, maintaining the same level as Q4 2020. Full year revenue reached $23.2 million, a 44% increase from 2020. Commercial revenue for the year was $21.6 million, up 54%, with recurring revenue showing remarkable growth of 100%. The company has reaffirmed its 2022 commercial revenue outlook of $27 million to $32 million, suggesting growth between 25% and 50%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
Rhea-AI Summary

Rapid Micro Biosystems (Nasdaq: RPID) announced its participation in the Cowen 42nd Annual Health Care Conference, scheduled for March 8, 2022, at 10:30 a.m. EST. CEO Rob Spignesi and CFO Sean Wirtjes will engage in a virtual Q&A session, accessible via a live webcast on the company's website. The session will also be archived for 90 days. The company specializes in automation solutions for healthcare product manufacturing, focusing on enhancing quality control processes through its flagship product, the Growth Direct System.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.31%
Tags
conferences

FAQ

What is the current stock price of Rapid Micro Biosystems (RPID)?

Rapid Micro Biosystems (RPID) last closed at $0.7350.

What is the market cap of Rapid Micro Biosystems (RPID)?

The market cap of Rapid Micro Biosystems (RPID) is approximately $37.4M.